In this study, we aim to explore the feasibility of a novel tumor target therapeutic strategy: Targeting PEPT1 to improve the antitumor efficacy of Doxorubicin in human HCC therapy. This evidence concerns the gene SLC15A1 and hepatocellular carcinoma.